FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder - Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY)

First Targeted Drug Approved for Blistering Skin Condition

(MedPage Today) -- The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced. Approval of the injectable...

Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid in Adults

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management.

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder - Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY)

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic autoimmune skin disorder. BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with underlying type 2 inflammation. The b…

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

Sanofi and Regeneron's Dupixent gets FDA approval for rare skin disease ...

Emerging Biologics in Treating Pemphigus and Bullous Pemphigoid

Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.